Pulmonary Hypertension Trial, Recruiting NCT05678062 Sponsor: University of Cape Town Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT05678062
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with preeclampsia (a pregnancy complication involving high blood pressure) and have also had new tonic-clonic seizures (a type of seizure involving stiffening and jerking of the body), as defined by the American College of Obstetricians and Gynecologists (ACOG)

Who may not be able to join:

  • People who have a long-term lung disease
  • People who have a connective tissue or collagen disorder (a condition affecting the body's connective tissues)
  • People who have HIV infection with a CD4 count below 200 cells/mm3 (a measure indicating a weakened immune system)
  • People who have long-term kidney or liver disease
  • People who have a urinary tract infection
  • People who have sepsis (a serious body-wide response to infection)
  • People whose body mass index (BMI) is above 50 kg/m2 (a measure of body weight relative to height)
  • People who have a history of seizure disorders (such as epilepsy)
  • People who have bleeding inside the skull or brain
  • People who have a history of a brain tumour, whether non-cancerous or cancerous

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Robert Dyer, MBChB, PhD, University of Cape Town

Phone: +27214045001

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Cape Town
Registry
ClinicalTrials.gov
Start date
21 November 2022
Est. completion
1 December 2024

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

The correlation between pulmonary interstitial syndrome (as identified by lung ultrasound), and cardiac dysfunction on echocardiography, in eclamptic women

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov